Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer

NCT04554927 | Recruiting

• 1 other identifier: WEBAPPAC
• Study Type: interventional
• Target: 438
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.

Conditions

Web-application; Breast Cancer; Hormono Therapy

Outcome Measures

Primary Outcomes (1)

• Observance of hormontherapy

  Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)

  18 months

Secondary Outcomes (2)

• Quality of life with self questionnaires

  18 months

• Quality of life with self questionnaires

  18 months

Study Arms (2)

WEB-application

EXPERIMENTAL

Other: WEB-Application

Standard accompaniment

ACTIVE COMPARATOR

Other: Standard accompaniment

Interventions

WEB-Application OTHER

The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).

WEB-application

Standard accompaniment OTHER

Personalized schedule of medical follow-up given to the patient

Standard accompaniment

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient \> 18 years old
• Breast cancer patient candidate for adjuvant hormone therapy
• Mastery of the French language
• Patient with a cell phone and an Internet connection
• Patient able to use a computer, smartphone, or tablet.
• Patient affiliated to a social security system
• Signing of informed consent prior to any specific study-related procedure

You may not qualify if:

• Patient who has previously received hormone therapy for cancer.
• Patient not trained in the use of the application
• Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study
• Patients with locoregional or metastatic recurrence
• Other history of cancer.
• Patient deprived of liberty, under guardianship or curatorship
• Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool
• Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons

Sponsors & Collaborators

• Centre Francois Baclesse: lead

Study Sites (1)

Centre François baclesse

Caen, 14000, France

RECRUITING

Related Publications (1)

• Gernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study. BMC Cancer. 2023 Aug 9;23(1):736. doi: 10.1186/s12885-023-11242-1.

  PMID: 37559004 DERIVED

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 14, 2020
• First Posted: September 18, 2020
• Study Start: September 3, 2020
• Primary Completion: October 11, 2024
• Study Completion: December 31, 2025
• Last Updated: September 22, 2025

Record last verified: 2025-08

Locations

FR (1)